Project Size
Aggregate 53,000 SF (Phases 1-3)
Schedule
Aug 2022
# Of Employees
50
Cost
Confidential
Maxcyte®
Location consolidation allows Flow for next-generation cell-based therapies.
On a solid foundation of more than 20 years’ experience perfecting the art of cell engineering, MaxCyte is opening exciting new possibilities in cell-based therapies with ExPERTTM instruments, bringing together best-in-class electroporation technology with seamless scalability. The challenge: Scattered operations and a lack of facility cohesion prevented the company from fully realizing the opportunity represented by the more than 50,000 ongoing cell and gene therapy clinical trials. Operations needed to be brought together and facilities repurposed and relocated for consolidation. Facility Logix offered the specialized, cross-disciplinary expertise necessary for success.
Addressing operational and scientific needs, navigating the Rockville real estate market.
Addressing the project with dedication and diverse expertise, Facility Logix answered all of the complex requirements—the essential needs of the scientific manufacturing environment as well as critical considerations of project management and economic development. Today, MaxCyte is thriving in the heart of Rockville in a repurposed office building that allows and supports leading-edge manufacturing, research and development, warehousing, and corporate office functions in a single high-performance facility. Now, MaxCyte's Flow Electroporation® Technology has the opportunity to enable the next generation of cell-based therapies, particularly in gene editing and immune-oncology.
- Ron Holtz, CFO, MaxCyte®, Inc.
Maxcyte®
Location consolidation allows Flow for next-generation cell-based therapies.
Project Size: Aggregate 53,000 SF (Phases 1-3)
Schedule: Aug 2022
# Of Employees: 50
Cost: Confidential
Location: Rockville, MD
On a solid foundation of more than 20 years’ experience perfecting the art of cell engineering, MaxCyte is opening exciting new possibilities in cell-based therapies with ExPERTTM instruments, bringing together best-in-class electroporation technology with seamless scalability. The challenge: Scattered operations and a lack of facility cohesion prevented the company from fully realizing the opportunity represented by the more than 50,000 ongoing cell and gene therapy clinical trials. Operations needed to be brought together and facilities repurposed and relocated for consolidation. Facility Logix offered the specialized, cross-disciplinary expertise necessary for success.
Addressing operational and scientific needs, navigating the Rockville real estate market.
Addressing the project with dedication and diverse expertise, Facility Logix answered all of the complex requirements—the essential needs of the scientific manufacturing environment as well as critical considerations of project management and economic development. Today, MaxCyte is thriving in the heart of Rockville in a repurposed office building that allows and supports leading-edge manufacturing, research and development, warehousing, and corporate office functions in a single high-performance facility. Now, MaxCyte's Flow Electroporation® Technology has the opportunity to enable the next generation of cell-based therapies, particularly in gene editing and immune-oncology.
- Ron Holtz, CFO, MaxCyte®, Inc.